State Trading Organisation (STO), in partnership with AstraZeneca, has introduced two groundbreaking respiratory health products to the Maldives: Symbicort Turbuhaler and Pulmicort Respules. The launch event, held on 7th December at the 24th floor of Dharumavantha Hospital, marks a significant milestone in the management of asthma and chronic obstructive pulmonary disease (COPD) in the country.
The event featured a keynote address by Dr. Rennis Davis, a renowned pulmonologist from India. Dr. Davis emphasised the importance of adhering to the Global Initiative for Asthma (GINA) guidelines, which focus on reducing the overuse of short-acting beta-agonists (SABA) and promoting maintenance and reliever therapy for better patient outcomes.
The gathering brought together approximately 60 physicians, fostering discussions on guideline-driven treatments aimed at improving the quality of care for asthma and COPD patients.
Symbicort Turbuhaler, an advanced dry powder inhaler, offers a user-friendly solution with fast and superior relief compared to traditional SABA relievers. Pulmicort Respules, designed for quick efficacy, dissolve through the airway mucus layer in just six minutes, delivering a strong pulmonary vasoconstrictive effect within 30 minutes. This innovative approach reduces asthma symptoms and the risk of exacerbations, providing an efficient alternative to systemic steroids.
STO’s introduction of these products underscores its commitment to addressing critical medical needs and enhancing healthcare services for the Maldivian community. These solutions represent a significant step forward in improving respiratory health outcomes across the country.
